文献速递瓣膜外科

经导管与外科主动脉瓣置换试验中非劣效性的贝叶斯解读:系统综述与荟萃分析

Bayesian interpretation of non-inferiority in transcatheter versus surgical aortic valve replacement trials: a systematic review and meta-analysis.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2023-01-01

该系统综述与荟萃分析纳入8项随机试验共8698例患者,比较经导管主动脉瓣置换(TAVR)与外科主动脉瓣置换(SAVR)。5年生存率TAVR为61.6%(95%CI 59.8-63.5%),SAVR为63.7%(95%CI 61.9-65.6%);6项试验(n=6370)5年全因死亡分析显示,在模糊先验下TAVR相对风险后验中位数为1.14(95%可信区间1.06-1.22),5年非劣效性不再可能。

要点

  • 8项随机试验共8698例患者,5年生存率TAVR 61.6% vs SAVR 63.7%。
  • 6项试验(n=6370)5年全因死亡相对风险后验中位数1.14(95%可信区间1.06-1.22)。
  • 基于不同非劣效界值,分析提示5年非劣效性不再可能。

核心结论

  • 在5年全因死亡率方面,TAVR不太可能仍非劣效于SAVR。

研究设计与样本

  • 系统综述与荟萃分析,检索3个电子数据库,纳入比较TAVR与SAVR的随机试验,共8项试验、8698例患者。

主要发现

  • Kaplan-Meier推导的5年生存率TAVR为61.6%(95%CI 59.8-63.5%),SAVR为63.7%(95%CI 61.9-65.6%)。
  • 6项试验(n=6370例)报告5年随访全因死亡率;在模糊先验下,TAVR全因死亡的相对风险后验中位数为1.14(95%可信区间1.06-1.22,相对风险<1.00的概率=0.01%,I²=0%)。
  • 采用频率学方法获得相似的点估计和不确定性度量。
  • 基于各种试验非劣效界值,分析结果提示5年非劣效性不再可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The concept of non-inferiority is widely adopted in randomized trials comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). However, uncertainty exists regarding the long-term outcomes of TAVR, and non-inferiority may be difficult to assess. We performed a systematic review and meta-analysis of randomized trials comparing TAVR and SAVR, with a specific emphasis on the non-inferiority margin for 5-year all-cause mortality. METHODS: A systematic search was applied to 3 electronic databases. Randomized trials comparing TAVR and SAVR were included. Bayesian methods were implemented to evaluate the posterior probability of non-inferiority at different trial non-inferiority margins under either a vague, Cauchy, or a literature-based prior. Primary outcomes were 5-year actuarial all-cause mortality, and the probability of non-inferiority at various transformed trial non-inferiority margins. Secondary outcomes were long-term survival and 1- and 2-year actuarial survival. RESULTS: Eight trials (n = 8698 patients) were included. Kaplan-Meier-derived 5-year survival was 61.6% (95% CI 59.8-63.5%) for TAVR, and 63.7% (95% CI 61.9-65.6%) for SAVR. Six trials (n = 6370 patients) reported all-cause mortality at 5-year follow-up. Under a vague prior, the posterior median relative risk for all-cause mortality of TAVR was 1.14, compared to SAVR (95% credible interval 1.06-1.22, probability of relative risk <1.00 = 0.01%, I2 = 0%). Similar results in terms of point estimate and uncertainty measures were obtained using frequentist methods. Based on the various trial non-inferiority margins, the results of the analysis suggest that non-inferiority at 5 years is no longer likely. CONCLUSIONS: It is unlikely that TAVR is still non-inferior to SAVR at 5 years in terms of all-cause mortality.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Heuts S, Kawczynski MJ, Sardari Nia P, et al. Bayesian interpretation of non-inferiority in transcatheter versus surgical aortic valve replacement trials: a systematic review and meta-analysis. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 37982737. doi:10.1093/icvts/ivad185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。